• Products & Services
We Know Consumer Habits Inside Out

Get insights that allow you to personalize messaging and deliver them to targeted segments for maximum ROI.

Audiences

Targeting based on actual purchase data, how they shop, brand affinities, lifestyle diets, and other purchase motivators.

  • Catalina in Action
Super-charge your sales with Catalina.

Learn how Catalina insights can help you personalize messaging and deliver them to targeted segments for maximum ROI.

CPG Growth Strategies for 2023 – How to Win with Real-Time Solutions

Kevin Hunter, Catalina’s Chief Commercial Officer and Head of Innovation, advises CPG marketers and retailers to lean into these five growth strategies in 2023: Connected TV, Shopper Marketing, In-store Incentives, Next Gen Personalization, and Omni-Channel Delivery and Optimization.

Catalina Launches Reach Extender

Catalina has introduced Catalina Reach Extender, which amplifies current digital offers by extending relevant printed offers at check-out to those who shop exclusively In-store. The retail data science, insights, and media company, 84.51°, is an early collaborator. 84.51° currently delivers personalized promotional offers to Kroger’s digitally engaged shoppers via its website, mobile app, and more broadly via its Loyal Customer Mailer.

Sales of Herbal Immune Supplements Rise While Vitamin Sales Decline During Q4 of 2022

During the final quarter of 2022, even as the U.S. grappled with a “tripledemic” of flu, RSV and COVID-19, unit sales of vitamins and health supplements declined over the prior year while average unit prices rose, according to shopper intelligence leader Catalina. A clear exception was Herbal Immune Supplements, unit sales of which shot up 48% while their average price declined by 4%.

Shoppers Turn to Herbal Immune Supplements as Vitamin Sales Decline

During the final quarter of 2022, even as the U.S. grappled with a “tripledemic” of flu, RSV and COVID-19, unit sales of vitamins and health supplements declined over the prior year while average unit prices rose. A clear exception was Herbal Immune Supplements, unit sales of which shot up 48% while their average price declined by 4%.

How is Tripledemic Affecting OTC Sales of Flu, RSV Remedies?

Catalina’s Shopper Intelligence data insights show a sharp increase in OTC flu and RSV treatment unit sales as prices rise.

OTC Cold & Flu Meds See YoY Increase

New insights from Catalina show that the 'tripledemic' is having a large impact on OTC medicine sales. Data Catalina shows that overall over-the-counter (OTC) cold and flu medicine increased in price by 12% in 2022, with private label sales slightly decreasing outside of the children’s category.

'Tripledemic' Spurs Rising Sales for Related OTC Products

Strike three! Catalina is keeping score of store sales related to the current "tripledemic" (flu, COVID and RSV -- respiratory syncytial virus), and the results are good -- for OTC marketers, if not the suffering public.

Catalina Reports Impact of ‘Tripledemic’ on Sales of O-T-C Flu and RSV Remedies

The U.S. “tripledemic” is in full swing causing unit sales of over-the-counter (O-T-C) treatment categories to rise by as much as 69%, according to Catalina’s Shopper Intelligence Platform.

Catalina Reports Impact of ‘Tripledemic’ on Sales of Over The Counter Flu and Respiratory Syncytial Virus (RSV) Remedies

The U.S. “tripledemic” is in full swing causing unit sales of over the counter (OTC) treatment categories to rise by as much as 70%. New COVID variants, an early and more serious flu season, plus a sharp uptick of respiratory virus infections (RSV) contributed to OTC cough, cold, RSV, and flu symptom-related products climbing an average of 19% for October-November 2022 compared to the same period a year ago.

INFOGRAPHIC: Catalina Reports Impact of ‘Tripledemic’ on Sales of OTC Remedies for Flu & RSV

The U.S. 'tripledemic' is in full swing causing unit sales of over the counter (OTC) treatment categories to rise by as much as 70%. New COVID variants, an early and more serious flu season, plus a sharp uptick of respiratory virus infections (RSV) contributed to OTC cough, cold, RSV, and flu symptom-related products climbing an average of 19% for October-November 2022 compared to the same period a year ago.

MORE LIKE THIS